35 Nixon Road
Bolton, ON L7E 1K1
Industry: Drug Manufacturers—Specialty & Generic
|Mr. Kenneth d'Entremont||CEO & Director||688.3k||N/A||N/A|
|Mr. Bill Poncy||Sr. VP of Commercial Operations - United States||439.69k||N/A||N/A|
|Mr. Michael David Adelman||Gen. Mang., U.S. Operations||576.85k||N/A||1971|
|Mr. Marcel Konrad||Chief Financial Officer||N/A||N/A||1976|
|Ms. Tina Byers CFA||Exec. of Investor Relations||N/A||N/A||N/A|
|Mr. Ian C. Wildgoose Brown||Gen. Counsel & Corp. Sec.||N/A||N/A||N/A|
|Mr. Brian Peters||VP of Sales & Marketing - United States||N/A||N/A||N/A|
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis psoriasis, and juvenile idiopathic arthritis; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also include Treosulfan, a conditioning agent used prior to stem cell transplantation; and Triamcinolone Hexacetonide for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Bolton, Canada.
Medexus Pharmaceuticals Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.